Methods of administering antitumor agent comprising...

Details Methods of administering antitumor agent comprising... Methods of administering antitumor agent comprising...

2011-01-04

2011-01-04

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S042000, C514S043000, C514S050000, C514S051000

Reexamination Certificate

active

07863255

ABSTRACT:
Antitumor treatment regimens comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone, or a salt thereof, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m2total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours. Compositions for providing the methods are also disclosed.

REFERENCES:
patent: 5616567 (1997-04-01), Sasaki et al.
patent: 5654420 (1997-08-01), Matsuda et al.
patent: 2559917 (1996-09-01), None
Galmarini et al. Lancet Oncol. (2002), vol. 3, pp. 415-424.
English language Abstract of JP 2559917 B2.
Matsuda et al., “Nucleosides and Nucleotides. 100. 2′-C-Cyano-2′-deoxy-1-β-D-arabinofuranosyl-cytosine (CNDAC): Design of a Potential Mechanism-Based DNA-Strand-Breaking Antineoplastic Nucleoside”,J. Med. Chem., vol. 34, pp. 2917-2919 (1991).
Azuma et al., “Nucleosides and Nucleotides. 122. 2′-C-Cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine and Its Derivatives. A New Class of Nucleoside with a Broad Antitumor Spectrum”,J. Med. Chem., vol. 36, pp. 4183-4189 (1993).
Azuma et al., “2′-C-Cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine: A Novel Anticancer Nucleoside Analog that Causes Both DNA Strand Breaks and G2Arrest”,Molecular Pharmacology, vol. 59, No. 4, pp. 725-731 (2001).
Azuma et al., “Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-Cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)”,Biochem.Pharmacol., vol. 61, pp. 1497-1507 (2001).
Therasse et al., “New Guidelines to Evaluate the Response to Treatment in Solid Tumors”,Journal of National Cancer Institute, vol. 92, No. 3, pp. 205-216 (2000).

Affiliated with

Also associated with

Rating

Methods of administering antitumor agent comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of administering antitumor agent comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering antitumor agent comprising... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2705995